Skip to main content
. 2020 Mar 5;16(9):1526–1535. doi: 10.7150/ijbs.42966

Figure 2.

Figure 2

Combination of GW9662 and αPD-L1 elicits more tumor-infiltrating T cells and anti-tumor cytokines in CD8+ TILs versus single agents. (A) Percentage of CD3+ T lymphocytes of live CD45+ cells from tumors isolated 13 days post tumor injection in female mice following various treatments as indicated. (B) Percentage of CD8+ T cells percentage (of CD45+CD3+ cells) in αPD-L1 and GW9662 combination treatment group. (C) Percentage of CD4+ T cells (of CD45+CD3+ cells). (D) Representative flow cytometry of the IFN-γ and TNF-α staining in CD45+CD3+CD8+ TILs. (E) IFN-γ+, (f) TNF-α+ and (G) dual positive IFN-γ+ TNF-α+ percentage gated on CD45+CD3+CD8+ T cells. (H) Mean fluorescent intensity (MFI) of IFN-γ, an indicator of cytokine production per cell in various treatment groups. N=4 mice per group. VEH: DMSO+αIgG/. αPD-L1: DMSO+αPD-L1. GW: GW9662+αIgG. αPD-L1+GW: αPD-L1+GW9662. Data represent mean ± SD. P values as indicated.